AbbVie vs Lilly

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...

10-Q Financial Filing Analysis for Lilly (2026-10-29)

Eli Lilly and Company reported strong financial results for the third quarter of 2026, driven by rapid uptake of its incretin portfolio. Total revenue reached $24.40 billion, up 39% year-over-year from $17.60 billion in Q3 2025, underpinned by massive volume expansion for Mounjaro ($10.72 billion, up 65%) and Zepbound ($5.35 billion, up 49%). Incretin medicines represented roughly two-thirds of total revenue for the first nine months of 2026. Consolidated net income for the quarter rose 16% to $6.45 billion ($7.22 diluted EPS), despite absorbing $4.18 billion in acquired in-process research and development (IPR&D) charges from external business development transactions including AtaiBeckley and Curevo. Operating cash flow expanded to $27.42 billion for the first nine months, allowing Lilly to fund aggressive manufacturing expansions ($8.44 billion in CapEx), strategic acquisitions ($10.69 billion net cash paid for acquisitions), and shareholder returns ($4.64 billion in dividends and $4.33 billion in share repurchases). While lower realized prices in the U.S. and China created pricing headwinds, Lilly's manufacturing efficiencies supported an 83.9% gross margin. Management continues to monitor pricing pressures from the Inflation Reduction Act, international reference pricing, and ongoing litigation regarding incretin compounding and patent enforcement.

• Q3 2026 revenue increased 39% year-over-year to $24.40 billion, with Mounjaro generating $10.72 billion and Zepbound generating $5.35 billion.
• Quarterly net income reached $6.45 billion ($7.22 diluted EPS), absorbing $4.18 billion in acquired in-process R&D charges primarily from asset acquisitions of AtaiBeckley and Curevo.
• For the first nine months of 2026, operating cash flow stood at $27.42 billion, funding $8.44 billion in capital expenditures, $18.2 billion in business development activity, and $4.33 billion in share buybacks.

West Pharma earnings prove it's not just a GLP-1 play

West Pharmaceutical Services reported strong Q3 2026 earnings, with adjusted EPS up 35.7% to $2.66 on sales of $874.5 million, beating analyst expectations. The company raised its full-year adjusted EPS guidance to $9.38-$9.48, citing robust demand for its premium drug-delivery components. While the GLP-1 boom, highlighted by Eli Lilly's 39% revenue growth, is a tailwind, West's growth is also driven by high-value component sales and margin expansion. Proprietary product sales grew 12.6%, with high-value components up 20.3% and now representing 53% of sales. Management expects operating margins to expand by nearly 300 basis points this year, supported by disciplined capital spending. The stock hit a 52-week high of $438.27, reflecting investor confidence in the company's diversified growth strategy.

• West Pharmaceutical Services reported Q3 2026 adjusted EPS of $2.66, up 35.7% year-over-year.
• Q3 sales rose 8.7% to $874.5 million.
• Full-year adjusted EPS guidance raised to $9.38-$9.48 from previous $8.85-$9.05.

Eli Lilly Debuts GLP-1 Ad Targeting Medicare Enrollees

Eli Lilly and Wieden+Kennedy Portland premiered a film called “A Life Covered” to raise awareness among Medicare Part D enrollees about newly available coverage for certain GLP-1 weight-management medications under a CMS demonstration called the Medicare GLP-1 Bridge. The ad — credited to directors Kwedar and Bentley, shot by Linus Sandgren and scored by Caroline Shaw — aims to inform seniors about access and cost (noted as $50/month under the demonstration). Lilly positioned the spot as a consumer awareness effort for patients and seniors; the campaign continues a multi-year partnership between Lilly and Wieden+Kennedy.

• Eli Lilly and Wieden+Kennedy Portland debuted a film titled “A Life Covered.”
• As of July 1, eligible Medicare Part D enrollees can receive certain GLP-1 medications for weight management at $50/month under a CMS demonstration called the Medicare GLP-1 Bridge.
• Lilly products Zepbound KwikPen and orforglipron (sold as Foundayo) are listed as covered under the demonstration and available to Medicare enrollees.